As per the terms of the licensing agreement, Bracco has been granted exclusive rights in Italy to commercialize and market Vitaros under the Bracco trademark.
The tie up allows Apricus to receive up to EUR5.5m in up-front, regulatory and sales milestone payments.
Further, over the life of the agreement, Apricus Bio will receive tiered, double-digit royalties based on Bracco’s sales of the product.
Apricus president and CEO Bassam Damaj said that this is the first in a series of commercialization agreements which they plan to execute for Vitaros.
"We look forward to working with Bracco and are confident in their ability to establish Vitaros as a major ED therapy," Damaj said.